Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling.

Date
2019-10-28Journal
Journal of General Internal MedicinePublisher
Springer NatureType
Article
Metadata
Show full item recordSee at
https://doi.org/10.1007/s11606-019-05460-2https://link.springer.com/article/10.1007%2Fs11606-019-05460-2
Sponsors
This study was funded with nonspecific faculty research funds provided by the University of Maryland, Baltimore, to Dr. Doshi.Keyword
Drug Labeling--standardsIdentifier to cite or link to this item
http://hdl.handle.net/10713/11247ae974a485f413a2113503eed53cd6c53
10.1007/s11606-019-05460-2
Scopus Count
Related articles
- Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.
- Authors: Shea MB, Stewart M, Van Dyke H, Ostermann L, Allen J, Sigal E
- Issue date: 2018 Nov
- Deficiencies in the reporting of VD and t(1/2) in the FDA approved chemotherapy drug inserts.
- Authors: D'Souza MJ, Alabed GJ
- Issue date: 2010 Feb 3
- Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.
- Authors: Guinn D, Madabushi R, Wang YM, Brodsky E, Zineh I, Maxfield K
- Issue date: 2020 Nov
- NP Safe Prescribing Of Controlled Substances While Avoiding Drug Diversion
- Authors: Dydyk AM, Sizemore DC, Haddad LM, Lindsay L, Porter BR
- Issue date: 2020 Jan
- Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
- Authors: Shaw DL, Dhruva SS, Ross JS
- Issue date: 2018 Dec